Muse Cell Therapy for Interstitial Cystitis Bladder Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for interstitial cystitis are ineffective, and there is a need for a novel therapeutic approach using stem cells that can effectively reduce pain and frequency of urination in patients.
Innovation Solution
A cell preparation containing SSEA-3 positive pluripotent Muse cells, which are isolated from mesenchymal tissue and enriched through stress treatment, is administered to the bladder to engraft and differentiate into bladder tissue, reducing inflammation and pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for interstitial cystitis, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent segments the heterogeneous mesenchymal cell population to isolate and enrich for specific pluripotent stem cells (SSEA-3 positive cells) that possess superior therapeutic properties. This segmentation allows selection of cells with higher differentiation potential and regenerative capacity, directly improving therapeutic effectiveness while using a targeted approach rather than broad conventional treatments
Solution Approach 2:
The patent applies stress treatment parameters (such as oxidative stress, mechanical stress, or chemical stress) to enrich for pluripotent stem cells from mesenchymal tissue. By changing the stress parameters during cell preparation, the method selectively enriches for cells with enhanced therapeutic potential, thereby improving treatment effectiveness without requiring complex surgical procedures
2Reliability
If iPS cells are used for therapy, then pluripotent stem cell potential is achieved, but procedural complexity and tumor risk increase
Solution Approach 1:
The patent extracts and isolates pluripotent stem cells directly from mesenchymal tissue without requiring the complex induction process used to create iPS cells. By taking out the desired pluripotent cells directly from adult tissue and enriching them through stress treatment, the method achieves therapeutic potential while avoiding gene introduction procedures and associated tumor risks
Solution Approach 2:
The patent uses a simpler, more direct cell preparation method that avoids the expensive and complex iPS cell induction process. The stress treatment enrichment method is more straightforward and can be performed with simpler protocols, reducing procedural complexity and potential risks while maintaining therapeutic effectiveness
3Reliability
If MSCs are used for treatment, then cell therapy is administered, but heterogeneity reduces therapeutic consistency
Solution Approach 1:
The patent segments the heterogeneous mesenchymal cell population by applying stress treatments that selectively enrich for pluripotent stem cells with specific characteristics (SSEA-3 positive). This segmentation creates a more homogeneous cell population with consistent therapeutic properties, ensuring reliable and consistent treatment outcomes across different patients
Solution Approach 2:
By changing the stress treatment parameters during cell preparation, the patent selectively enriches for cells with specific properties that ensure therapeutic consistency. The stress parameters are optimized to isolate cells with high pluripotency and regenerative capacity, creating a standardized cell product with predictable and consistent therapeutic effects
Data Source
AI summary
The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.